No more switching between PACS, PSA density calculation feature and PI-RADS support; Quantib® Prostate offers one workflow including all essential prostate MRI reading features plus the generation of a standardized report.
Semi-automated combination of bi-parametric data supports ROI determination and enables prostate lesion evaluation. AI-bolstered segmentation allows for easy and fast determination of lesion volume.
The AI software can be installed onsite or on the cloud and is easily integrated with PACS. The output of the software is also compatible with certain ultrasound systems*.
Quantib® Prostate is currently 510(k) cleared by the FDA for distribution in the US. This product complies with all applicable requirements of the European MDR (2017/745). Availability in EU countries upon request. Not commercially available in other countries.
* For more information about the product's compatibility with ultrasound systems, please contact us.
Edward Steiner, MD | The York/WellSpan Advanced Prostate Care Center
Martina Martins, MD | Swiss International Prostate Center
Download the brochure to discover the benefits of using Quantib® Prostate and its features.
Download the white paper to discover how to improve the clinical pathway of prostate cancer with AI and our solution: Quantib® Prostate.
Quantib® Prostate provides a comprehensive report including volume, location as per PI-RADS regions, PI-RADS scoring and kinetic curves per lesion.